BiotechTube

AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + Selumetinib

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscle Invasive Bladder Cancer

Conditions

Muscle Invasive Bladder Cancer

Trial Timeline

Dec 28, 2016 → Jan 30, 2026

NCT ID
NCT02546661

About AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + Selumetinib

AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + Selumetinib is a phase 1 stage product being developed by AstraZeneca for Muscle Invasive Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02546661. Target conditions include Muscle Invasive Bladder Cancer.

What happened to similar drugs?

2 of 20 similar drugs in Muscle Invasive Bladder Cancer were approved

Approved (2) Terminated (0) Active (18)
✅Botulinum toxin type A + PlaceboIpsenApproved
✅prabotulinumtoxinA-xvfsEvolusApproved
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
🔄EperisoneEisaiPhase 3
🔄Botulinum Toxin Type AAbbViePhase 3
🔄BOTOX + PlaceboAbbViePhase 3
🔄BOTOX + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02546661Phase 1Active

Competing Products

20 competing products in Muscle Invasive Bladder Cancer

See all competitors
ProductCompanyStageHype Score
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
EperisoneEisaiPhase 3
40
LY2495655 + PlaceboEli LillyPhase 2
35
HRS-9190Jiangsu Hengrui MedicinePhase 1
29
HRS-9190 for InjectionJiangsu Hengrui MedicinePhase 1
29
Botulinum Toxin Type AAbbViePhase 3
40
BOTOX + PlaceboAbbViePhase 3
40
BOTOX + PlaceboAbbViePhase 3
40
BOTOX + Placebo for BOTOXAbbViePhase 3
40
BOTOX + PlaceboAbbViePhase 3
40
Durvalumab + Tremelimumab + Enfortumab VedotinAstraZenecaPhase 3
44
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
44
Durvalumab + OleclumabAstraZenecaPhase 1
29
Durvalumab + Cisplatin + GemcitabineAstraZenecaPhase 3
44
Durvalumab + BCGAstraZenecaPhase 3
44
Durvalumab + MonalizumabAstraZenecaPhase 2
42
Durvalumab (Imfinzi) + TremelimumabAstraZenecaPhase 2
27